194 related articles for article (PubMed ID: 35348261)
1. Medical management of Cushing's disease: When and how?
Castinetti F
J Neuroendocrinol; 2022 Aug; 34(8):e13120. PubMed ID: 35348261
[TBL] [Abstract][Full Text] [Related]
2. Cushing's disease: role of preoperative and primary medical therapy.
Castinetti F
Pituitary; 2022 Oct; 25(5):737-739. PubMed ID: 35780261
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of ketoconazole as a treatment for Cushing's disease in a retrospective cohort.
Viecceli C; Mattos ACV; Costa MCB; de Melo RB; Rodrigues TDC; Czepielewski MA
Front Endocrinol (Lausanne); 2022; 13():1017331. PubMed ID: 36277689
[TBL] [Abstract][Full Text] [Related]
4. Ketoconazole as second-line treatment for Cushing's disease after transsphenoidal surgery: systematic review and meta-analysis.
Viecceli C; Mattos ACV; Hirakata VN; Garcia SP; Rodrigues TDC; Czepielewski MA
Front Endocrinol (Lausanne); 2023; 14():1145775. PubMed ID: 37223017
[TBL] [Abstract][Full Text] [Related]
5. Fluconazole for Hypercortisolism in Cushing's Disease: A Case Report and Literature Review.
Zhao Y; Liang W; Cai F; Wu Q; Wang Y
Front Endocrinol (Lausanne); 2020; 11():608886. PubMed ID: 33391186
[TBL] [Abstract][Full Text] [Related]
6. How best to monitor the specific side effects of medical treatments of Cushing's disease.
Castinetti F
Best Pract Res Clin Endocrinol Metab; 2022 Dec; 36(6):101718. PubMed ID: 36435719
[TBL] [Abstract][Full Text] [Related]
7. Clinical Utility of Osilodrostat in Cushing's Disease: Review of Currently Available Literature.
Perosevic M; Tritos NA
Drug Des Devel Ther; 2023; 17():1303-1312. PubMed ID: 37143705
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological Treatment of Cushing's Syndrome.
Castinetti F
Arch Med Res; 2023 Dec; 54(8):102908. PubMed ID: 37977919
[TBL] [Abstract][Full Text] [Related]
9. Prolonged adrenal insufficiency following discontinuation of osilodrostat treatment for intense hypercortisolism.
Ferriere A; Salenave S; Puerto M; Young J; Tabarin A
Eur J Endocrinol; 2024 Jan; 190(1):L1-L3. PubMed ID: 38123490
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Cushing's syndrome with osilodrostat: practical applications of recent studies with case examples.
Fleseriu M; Biller BMK
Pituitary; 2022 Dec; 25(6):795-809. PubMed ID: 36002784
[TBL] [Abstract][Full Text] [Related]
11. The dopaminergic control of Cushing's syndrome.
Pivonello R; Pivonello C; Simeoli C; De Martino MC; Colao A
J Endocrinol Invest; 2022 Jul; 45(7):1297-1315. PubMed ID: 35460460
[TBL] [Abstract][Full Text] [Related]
12. PPAR-gamma in Cushing's disease.
Heaney AP
Pituitary; 2004; 7(4):265-9. PubMed ID: 16416039
[TBL] [Abstract][Full Text] [Related]
13. A critical reappraisal of bilateral adrenalectomy for ACTH-dependent Cushing's syndrome.
Reincke M; Ritzel K; Oßwald A; Berr C; Stalla G; Hallfeldt K; Reisch N; Schopohl J; Beuschlein F
Eur J Endocrinol; 2015 Oct; 173(4):M23-32. PubMed ID: 25994948
[TBL] [Abstract][Full Text] [Related]
14. Recurrent Cushing's syndrome after adrenal autotransplantation.
Yesil S; Demir T; Akinci B; Ozdogan O; Gazioglu N; Hatemi H
Exp Clin Endocrinol Diabetes; 2009 Oct; 117(9):470-2. PubMed ID: 19885999
[TBL] [Abstract][Full Text] [Related]
15. Approach to the Patient Treated with Steroidogenesis Inhibitors.
Castinetti F; Nieman LK; Reincke M; Newell-Price J
J Clin Endocrinol Metab; 2021 Jun; 106(7):2114-2123. PubMed ID: 33675650
[TBL] [Abstract][Full Text] [Related]
16. Updates in adrenal steroidogenesis inhibitors for Cushing's syndrome - A practical guide.
Varlamov EV; Han AJ; Fleseriu M
Best Pract Res Clin Endocrinol Metab; 2021 Jan; 35(1):101490. PubMed ID: 33707082
[TBL] [Abstract][Full Text] [Related]
17. Classic and recent etiologies of Cushing's syndrome: diagnosis and therapy.
Beauregard C; Dickstein G; Lacroix A
Treat Endocrinol; 2002; 1(2):79-94. PubMed ID: 15765624
[TBL] [Abstract][Full Text] [Related]
18. Medical treatment of Cushing's Disease.
Cuevas-Ramos D; Fleseriu M
Minerva Endocrinol; 2016 Sep; 41(3):324-40. PubMed ID: 26977887
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
Pivonello R; Fleseriu M; Newell-Price J; Bertagna X; Findling J; Shimatsu A; Gu F; Auchus R; Leelawattana R; Lee EJ; Kim JH; Lacroix A; Laplanche A; O'Connell P; Tauchmanova L; Pedroncelli AM; Biller BMK;
Lancet Diabetes Endocrinol; 2020 Sep; 8(9):748-761. PubMed ID: 32730798
[TBL] [Abstract][Full Text] [Related]
20. DIAGNOSIS OF ENDOCRINE DISEASE: Differentiation of pathologic/neoplastic hypercortisolism (Cushing's syndrome) from physiologic/non-neoplastic hypercortisolism (formerly known as pseudo-Cushing's syndrome).
Findling JW; Raff H
Eur J Endocrinol; 2017 May; 176(5):R205-R216. PubMed ID: 28179447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
